Broth microdilution susceptibility testing of Brucella species: Quality control limits for ten antimicrobial agents against three standard quality control strains

Journal of Clinical Microbiology

Volumn 43, Issue 11, 2005, Pages 5804-5807

  Brown, Steven D ^a   Traczewski, Maria M ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIOLOGICAL WARFARE; BROTH MICRODILUTION SUSCEPTIBILITY TESTING; BRUCELLA; BRUCELLA ABORTUS; BRUCELLA MELITENSIS; BRUCELLA SUIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; INCUBATION TIME; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; QUALITY CONTROL; SPECIES DIFFERENTIATION; STANDARD;

ANTI-INFECTIVE AGENTS; BIOTERRORISM; BRUCELLA; CULTURE MEDIA; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

BRUCELLA; BRUCELLA MELITENSIS; BRUCELLA MELITENSIS BIOVAR ABORTUS; BRUCELLA MELITENSIS BIOVAR SUIS;

EID: 27744588741     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.11.5804-5807.2005     Document Type: Article

References (17)

1. Ariza, J., F. Gudiol, R. Pallares, P. F. Viladrich, G. Rufi, J. Corredoira, and M. R. Miravitlles. 1992. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann. Intern. Med. 117:25-30.
2. Barry, A. L., P. C. Fuchs, R. N. Jones, et al. 1989. Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Diagn. Microbiol. Infect. Dis. 12:413-420.
3. Garcia-Rodriguez, J. A., J. L. Munoz Bellido, M. J. Fresnadillo, and I. Trujillano. 1993. In vitro activities of new macrolides and rifapentine against Brucella spp. Aritimicrob. Agents Chemother. 37:911-913.
4. Hall, W. H. 1990. Modern chemotherapy for brucellosis in humans. Rev. Infect. Dis. 12:1060-1099.
5. Hall, W. H., and R. E. Manion. 1970. In vitro susceptibility of Brucella to various antibiotics. Applied Microbiol. 20:600-604.
6. Hussain, Q. S. M., M. Akhtar, Y. Ueno, and M. B. Al-Sibai. 1989. Susceptibility of Brucella melitensis to fluoroquinolones. Drugs Exp. Clin. Res. 15(10):483-485.
7. Khan, M. Y., M. Dizon, and F. W. Kiel. 1989. Comparative in vitro activities of ofloxacin. difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob. Agents Chemother. 33:1409-1410.
8. King, A. 2001. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother. 48(Suppl. S1): 77-80.
9. Landinez, R., J. Linares, E. Loza, J. Martinez-Beltran, R. Martin, and F. Baquero. 1992. In vitro activity of azithromycin and tetracycline against 358 clinical isolates of Brucella melitensis. Eur. J. Clin. Microbiol. Infect. Dis. 11:265-267.
10. Lang, R., M. Banai, M. Lishner, and E. Rubinstein. 1995. Brucellosis. Int. J. Antimicrob. Agents 5:203-208.
11. Lopez-Merino, A., A. Contreras-Rodriguez, R. Migranas-Ortiz, R. Orrantia-Gradin, G. M. Hernandez-Oliva, A. T. Y. Gutierrez-Rubio, and O. Cardenosa. 2004. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect. Dis. 36:636-638.
12. Montejo, J. M., I. Alberola, P. Glez-Zarate, A. Alvarez, J. Alonso, A. Canovas, and C. Aguirre. 1993, Open, randomized therapeutic trial of six anti-microbial regimens in the treatment of human brucellosis. Clin. Infect. Dis. 16:671-676.
13. Mortensen, J. E., D. G. Moore, J. E. Clarridge, and E. J. Young. 1986. Antimicrobial susceptibility of clinical isolates of Brucella. Diagn. Microbiol. Infect. Dis. 5:163-169.
14. National Committee for Clinical Laboratory Standards. 2003 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. National Committee for Clinical Laboratory Standards. 2001. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. Robinson-Dunn, B. 2002. The microbiology laboratory's role in response to bioterrorism. Arch. Pathol. Lab. Med. 126:291-294.
17. Trujillano-Martin, I., E. Garcia-Sanchez, I. M. Martinez, M. J. Fresnadillo, J. E. Garcia-Sanchez, and J. A. Garcia-Rodriguez. 1999. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob. Agents Chemother. 43:194-195.